HQL
NYSE:HQL
Tekla Life Sciences Investors
- Stock
12.70
−1.01%
−0.95
news - Jul 21, 2025 - 10:12
Stephens Inc. AR Purchases 6,947 Shares of abrdn Life Sciences Investors (NYSE:HQL)
Stephens Inc. AR increased its stake in abrdn Life Sciences Investors (NYSE:HQL) by 56.1% in Q1 2025, owning 19,336 shares worth $245,000. Other hedge funds like Wealthcare Advisory Partners LLC and Cambridge Investment Research Advisors Inc. also added to their positions. Saba Capital Management sold 11,419 shares, reducing its stake. The company recently paid a $0.43 quarterly dividend with a 13% yield, and its stock has a 50-day moving average of $12.70 and 200-day average of $12.91.
defenseworld.netnews - Jun 18, 2025 - 08:16
NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Citigroup
Citigroup initiated coverage on NewAmsterdam Pharma (NASDAQ:NAMS), issuing a buy rating and $42.00 price target. Other analysts, including Needham & Company, Stifel Nicolaus, and Scotiabank, have also issued reports on the stock. The company's stock opened at $18.49, with a market cap of $2.08 billion and negative earnings results. Director James N. Topper increased his stake, and hedge funds adjusted their holdings. The firm develops therapies for metabolic diseases.
defenseworld.netnews - Jun 04, 2025 - 09:15
Jane Street Group LLC Takes $290,000 Position in Abrdn Life Sciences Investors (NYSE:HQL)
Jane Street Group LLC and other institutional investors have increased their stakes in Abrdn Life Sciences Investors (NYSE:HQL), with the company announcing a quarterly dividend. The stock's price range and moving averages are also detailed, along with an insider transaction involving Saba Capital Management.
defenseworld.netnews - May 31, 2025 - 07:27
abrdn Life Sciences Investors Q1 2025 Commentary
abrdn Life Sciences Investors released a Q1 2025 commentary report analyzing performance and trends in the life sciences investment sector.
seekingalpha.comnews - May 26, 2025 - 09:04
Northern Trust Corp Makes New Investment in Upstream Bio, Inc. (NASDAQ:UPB)
Northern Trust Corp and other institutional investors increased their stakes in Upstream Bio, Inc. (NASDAQ:UPB) in the fourth quarter, with Northern Trust purchasing 143,721 shares valued at $2.36 million. The company reported Q1 earnings of ($0.51) EPS, missing analyst estimates, and operates in biotechnology to develop treatments for respiratory and inflammatory diseases.
defenseworld.netDescription
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare...Show More
Earnings
Earnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus